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Abstract
Streptococcal toxic shock syndrome (STSS) is a severe invasive infection characterized by the sudden onset of shock and
multiorgan failure; it has a high mortality rate. Although a number of studies have attempted to determine the crucial
factors behind the onset of STSS, the responsible genes in group A Streptococcus have not been clarified. We previously
reported that mutations of csrS/csrR genes, a two-component negative regulator system for multiple virulence genes of
Streptococcus pyogenes, are found among the isolates from STSS patients. In the present study, mutations of another
negative regulator, rgg, were also found in clinical isolates of STSS patients. The rgg mutants from STSS clinical isolates
enhanced lethality and impaired various organs in the mouse models, similar to the csrS mutants, and precluded their being
killed by human neutrophils, mainly due to an overproduction of SLO. When we assessed the mutation frequency of csrS,
csrR, and rgg genes among S. pyogenes isolates from STSS (164 isolates) and non-invasive infections (59 isolates), 57.3% of
the STSS isolates had mutations of one or more genes among three genes, while isolates from patients with non-invasive
disease had significantly fewer mutations in these genes (1.7%). The results of the present study suggest that mutations in
the negative regulators csrS/csrR and rgg of S. pyogenes are crucial factors in the pathogenesis of STSS, as they lead to the
overproduction of multiple virulence factors.
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Introduction
Streptococcus pyogenes (group A Streptococcus; GAS) is one of the
most common human pathogens. It causes a wide variety of
infections, ranging from uncomplicated pharyngitis and skin
infections to severe and even life-threatening manifestations, such
as necrotizing fasciitis (NF) and bacteremia. Several streptococcal
virulence factors, including pyrogenic exotoxins, streptokinase,
and streptolysins, are reportedly involved in these diseases.
Streptococcal toxic shock syndrome (STSS) is a severe invasive
infection that has been recently characterized by the sudden onset
of shock and multiorgan failure; it has a high mortality rate,
ranging from 30% to 70% [1]. There is controversy as to whether
the cause of STSS largely depends on host factors or bacterial
factors. Although many studies have sought to determine the
crucial factors behind the onset of STSS, the responsible GAS
genes have not been clarified.
Recently, we and others have reported that mutations in the csrS
(covS) gene—a sensor gene of a two-component regulatory
system—were detected in a panel of clinical isolates from severe
invasive streptococcal infections, but not in non-STSS isolates
[2–4]. Mutations in the gene caused an increased expression of
various virulence genes; the upregulation of streptolysin O (SLO)
induced necrosis of neutrophils and prompted the escape of csrS
mutated strains from being killed by neutrophils, resulting in
increased virulence in lethality in the mouse model [2].
Complementation of the wild csrS gene into csrS-mutated STSS
isolates dramatically decreased their virulence in lethality [2].
Similarly, csrR (covR) mutations were found in the clinical isolates of
STSS patients [5]. Such results suggest that csrS/csrR mutations
are closely associated with the onset of STSS.
However, several study groups that investigated the csrS/csrR
gene sequence in each STSS isolate [3,4,6,7] also report that there
is no mutation in the csrS/csrR gene of STSS isolates [4]. These
results raise questions as to how frequently STSS isolates have
mutations in the csrS/csrR genes in a mass of isolates, and what
mutations other than csrS/csrR genes may be responsible for the
onset of STSS.
In this study, we sequenced the csrS/csrR genes of 164 GAS
strains that have been isolated from STSS patients in Japan since
1992. Almost one-half of the STSS isolates had a mutation in the
csrS/csrR genes. In addition, we found a mutation in the rgg (ropB)
gene, instead of the csrS/csrR genes, in the clinical isolates of
patients with STSS. Since the rgg gene negatively regulates various
virulence genes in a manner similar to that of the csrS gene, a
mutation of the rgg gene in STSS clinical isolates increased the
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the mouse model. Such mutations were detected at a high
frequency in more than 50% of STSS isolates. These findings
suggest that mutations in the negative regulators such as csrS/csrR
and rgg of S. pyogenes bring about overproduction of a number of
virulence factors, such as SLO, and play a crucial role in the onset
of STSS.
Results
Mutation frequency of the csrS/csrR gene in STSS isolates
In our previous study, we reported that there were various types
of mutations in the csrS gene of emm49 clinical isolates from STSS
patients [2] and in the csrR gene in emm3 clinical isolates from STSS
patients [5]. These findings strongly suggest that csrS/csrR mutations
play important roles in the pathogenesis of STSS. To evaluate the
frequency of these csrS/csrR mutations in isolates from clinical cases
of STSS [8], we sequenced the csrS and csrR genes in STSS clinical
isolates from sterile sites (164 isolates) and non-STSS clinical isolates
from non-sterile sites (59 isolates). The diagnoses, sites of bacteria
isolation, and characteristics of S. pyogenes isolates are described in
Table 1.Ofthe 164STSSclinicalS.pyogenesisolates,55isolates(csrS,
46 isolates; csrS + rgg, 9 isolates) (33.5%) had mutations in the csrS
gene, 19 isolates (csrR, 13 isolates; csrR + rgg, 6 isolates) (11.6%) had
mutations in the csrR gene, and 2 isolates (1.2%) had mutations in
both genes (Tables 1 and 2). The csrS and csrR genes of these isolates
had deletions, point mutations, or insertions that created non-
functional CsrS and CsrR products, as shown previously [2,4,5].
Therefore, 76 isolates (46.3%) had mutations in the csrS and/or csrR
genes, while the remaining 88 STSS isolates (53.7%) had mutations
in neither csrS nor csrR (Tables 1 and 2). On the other hand, non-
STSSGASisolateshad a significantly lower number ofmutationsin
the genes [csrS mutation, 1.69% (1/59); csrR mutation, 0% (0/59);
total, 1.69% (1/59); p=0.00000000062 by x
2 analysis]. Although
csrS/csrR mutations were more common among STSS isolates
examined than among non-STSS isolates, they were not present in
all STSS isolates. This may suggest that mutations in other
regulatory genes may also be found among STSS isolates.
rgg or csrS mutations in STSS clinical isolates
To identify novel bacterial factors that may contribute to the
pathogenesis of STSS, we next investigated the expression pattern
of virulence factors in S. pyogenes isolates. We determined the
sequence of the csrS/csrR genes from a panel of emm-matched GAS
isolated from STSS patients; NIH1 (also called SSI-1), NIH3,
NIH8, NIH34, NIH152-3, NIH249, NIH327, and NIH352 were
clinical isolates of the emm3 genotype from STSS and C500,
OT22, and K33 were emm3 non-STSS isolates (Tables 1 and S1).
A mutation in the csrS gene was found in NIH152-3, NIH249,
NIH327, and NIH352 of the STSS isolates; however, the other
STSS and non-STSS GAS isolates had mutations in neither the
csrS nor the csrR gene (data not shown). To determine whether
other emm3 STSS strains have possible mutations in their genomes,
we used comparative genome sequencing (CGS) [9], a microarray
hybridization-based method developed to search for single-
nucleotide polymorphisms (SNPs) and insertion–deletion sites
within a genome between emm3 STSS and non-STSS isolates. We
found several genes with SNPs in the NIH1 genome in comparison
with that of non-invasive isolates K33. Three (codY, csrR and rgg)o f
them had non-synonymous amino acid change in NIH1 but not in
K33 and C500 (Table S2). We further sequenced these 3 genes in
other non-invasive isolate, OT22 and STSS isolates, NIH3, NIH8
and NIH34. A couple of genetic differences which affect amino
acid sequence were detected between the STSS and non-STSS
GAS isolates (Table 3). All four STSS isolates (NIH1, NIH3,
NIH8, and NIH34) had some difference in SPs1742 (Rgg) but not
in non-STSS isolates (C500, OT22, and K33) (Table 3). SPs1742
is identified as the rgg gene, a transcriptional regulator of multiple
genes [10–13], although the role of the rgg gene is controversial
[14].
Increased SLO expression in STSS isolates with csrS or rgg
mutations
We [2] and others [4] have previously reported that STSS
emm49 and emm1 clinical isolates exhibit a higher expression of the
SLO gene (slo) than non-STSS isolates, due to a mutation in the
csrS gene. Therefore, we examined whether a panel of emm3-
genotyped STSS isolates possessing mutations in the csrS or rgg
gene and emm3 non-STSS isolates lacking mutations could
produce SLO (i.e., secretion of SLO in the culture supernatant).
The comparison of the supernatants at the same growth condition
(data not shown) showed that larger amounts of SLO were
secreted by STSS isolates possessing mutations in the csrS gene
(NIH152, NIH249, NIH327, and NIH352) or rgg gene (NIH1,
NIH3, NIH8, and NIH34) than by non-STSS isolates (C500,
OT22, and K33) (Figure 1). These data suggest that rgg mutations
may be related to an increased expression of SLO, as observed in
the case of csrS mutations. To clarify the role of rgg gene mutation
in STSS isolates in terms of SLO production, we created the rgg
mutants K33rgg and OT22rgg, non-STSS isolates into which an rgg
mutation had been introduced. They exhibited increased SLO
secretion, as observe with STSS isolates (Figure 1). In contrast,
when an intact rgg gene was integrated into the genomic DNA of
the STSS isolates NIH8 and NIH34 (NIH8rgg
+ and NIH34rgg
+),
the SLO secretion was decreased to the level of that in non-STSS
isolates (Figure 1). Taken together, it appears that the mutation of
the rgg gene was responsible for increased SLO production in the
culture supernatant as that of csrS gene was.
Enhanced expression of various virulence genes in STSS
isolates is attributed to mutation of the rgg gene
It has been reported that Rgg influences the transcription of
many virulence-associated genes in S. pyogenes [10–13]. To test the
possibility that the transcriptional expression levels of virulence
genes are regulated by the function of the rgg gene, we performed
Author Summary
Group A streptococcus (GAS) causes life-threatening severe
invasive diseases, including necrotizing fasciitis and
streptococcal toxic shock-like syndrome. Although many
studies have attempted to determine factors that are
crucial for the onset of streptococcal toxic shock syndrome
(STSS), bacterial factors responsible for it have not been
clarified. By comparing genome sequences of clinical GAS
isolates from STSS with those of non-invasive infections,
we showed that mutations of negative regulator genes
(csrS, csrR, rgg) were detected at a high frequency of more
than 50% in STSS isolates, but at a low frequency of less
than 2% in non-invasive isolates. These mutations of
negative regulators were found in various emm-genotyped
STSS isolates but not in a particular emm genotype. These
mutants enhanced virulence in mouse models. Such
results indicated that mutations of bacterial negative
regulators are crucial for the pathogenesis of STSS due
to the overproduction of multiple virulence factors under
the de-repressed conditions.
Highly Frequent Mutations in STSS Isolates
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Diagnosis
NIH No.
Strain
name
Site of
bacterial
isolation
emm
type csrR csrS rgg
Increased
SLO,
production
CsrS/CsrR and
Rgg amino acid
sequence alterations Accession No. Reference
STSS NIH136 blood 1 mut ++ + CsrR, ArgRSer at aa 119 CsrR, AB517819 This study
NIH447 blood 1 mut ++ + CsrR, AspRGlu at aa 53 CsrR, AB517877 This study
NIH44 blood 1 + mut ++ CsrS, delete Glu at aa 252,
and LeuRVal at aa 253
CsrS, AB517809 This study
NIH73 blood 1 + mut ++ CsrS, 5 bp delete = stop at aa 407 CsrS, same as TK76 This study
NIH83 blood 1 + mut ++ CsrS, 5 bp delete = stop at aa 407 CsrS, same as TK76 This study
NIH102 ascites 1 + mut ++ CsrS, 1 bp delete = stop at aa 76 CsrS, AB517817 This study
NIH205 soft tissue 1 + mut ++ CsrS, GlnRArg at aa 388 CsrS, AB517823 This study
NIH202-2 blood 1 + mut ++ CsrS, 1 bp delete = stop at aa 35 CsrS, same as NIH156-1 This study
NIH213-3 blood 1 + mut ++ CsrS, 1 bp delete = stop at aa 35 CsrS, same as NIH156-1 This study
NIH220-1 blood 1 + mut ++ CsrS, GlyRVal at aa 457 CsrS, AB517828 [33]
NIH222 soft tissue 1 + mut ++ CsrS, AlaRSer at aa 206 CsrS, AB517829 This study
NIH235 blood 1 + mut ++ CsrS, 1 bp delete = stop at aa 35 CsrS, same as NIH156-1 This study
NIH243-1 blood 1 + mut ++ CsrS, GlyRArg at aa 291 CsrS, AB517834 This study
NIH253-1 blood 1 + mut ++ CsrS, 1 bp delete = stop at aa 457 CsrS, AB517835 This study
NIH286 blood 1 + mut ++ CsrS, IleRTyr at aa 381
and HisRArg at aa 437
CsrS, AB517845 This study
NIH314 rubor site 1 + mut ++ CsrS, 11 bp insert = stop at aa 39 CsrS, same as NIH287-1 This study
NIH397 blood 1 + mut ++ CsrS, 1 bp delete = stop at aa 35 CsrS, same as NIH156-1 This study
TK1097 soft tissue 1 ++mut + Rgg, LysRAsn at aa 45 Rgg, AB517806 This study
NIH60 blood 1 ++mut + Rgg, SerRPro at aa 103 Rgg, AB517813 This study
NIH91 blood 1 ++mut + Rgg, TyrRPhe at aa 271 Rgg, AB517816 This study
NIH186 blood 1 ++mut + Rgg, point mutation = stop at aa 69 Rgg, AB517824 [34]
NIH293 blood 1 ++mut + Rgg, CysRTyr at aa 249 Rgg, AB517848 This study
NIH374-2 wound 1 ++mut + Rgg, 1 bp insert = stop at aa 139 Rgg, AB517861 This study
NIH390 soft tissue 1 ++mut + Rgg, 6 bp insert = insert Apn
and Ile between aa 139 and aa 140
Rgg, AB517865 This study
NIH409 blood 1 ++mut + Rgg, ValRAla at aa 148 Rgg, AB517870 This study
NIH445 blood 1 ++mut + Rgg, LeuRPro at aa 95 Rgg, AB517876 This study
NIH75 blood 1 mut mut ++ CsrR, AlaRAsp at aa 111;
CsrS, ProRLys at aa 220
CsrR, AB517814;
CsrS, AB517815
This study
NIH381-1 wound 1 mut + mut + CsrR, AlaRVal at aa 96;
Rgg, LeuRPro at aa 109
CsrR, AB517863;
Rgg, AB517864
This study
NIH366 blood 1 + mut mut + CsrS, 1 bp delete = stop at aa 35;
Rgg, delete from aa 129 to aa 247
CsrS, same as NIH156-1;
Rgg, AB517857
This study
NIH17 blood 1 +++ -W T s e q u e n c e [ 3 5 ]
NIH68 blood 1 +++ - WT sequence This study
NIH94-2 blood 1 +++ - WT sequence This study
NIH111 blood 1 +++ - WT sequence This study
NIH135 soft tissue 1 +++ - WT sequence This study
NIH150 Joint fluid 1 +++ - WT sequence This study
NIH153 wound 1 +++ - WT sequence This study
NIH165-1 blood 1 +++ - WT sequence This study
NIH185 blood 1 +++ - WT sequence This study
NIH187 blood 1 +++ -W T s e q u e n c e [ 3 6 ]
NIH188-1 blood 1 +++ - WT sequence This study
NIH195 amniotic fluid 1 +++ - WT sequence This study
NIH201 Joint fluid 1 +++ - WT sequence This study
NIH204-1 muscle 1 +++ - WT sequence This study
NIH214 blood 1 +++ - WT sequence This study
Highly Frequent Mutations in STSS Isolates
PLoS Pathogens | www.plospathogens.org 3 April 2010 | Volume 6 | Issue 4 | e1000832Diagnosis
NIH No.
Strain
name
Site of
bacterial
isolation
emm
type csrR csrS rgg
Increased
SLO,
production
CsrS/CsrR and
Rgg amino acid
sequence alterations Accession No. Reference
NIH223 soft tissue 1 +++ - WT sequence This study
NIH224 effusion 1 +++ - WT sequence This study
NIH225 blood 1 +++ -W T s e q u e n c e [ 3 3 ]
NIH242 soft tissue 1 +++ -W T s e q u e n c e [ 3 6 ]
NIH270 pleural effusion 1 +++ - WT sequence This study
NIH261 blood 1 +++ - WT sequence This study
NIH291-1 blood 1 +++ - WT sequence This study
NIH298 soft tissue 1 +++ - WT sequence This study
NIH304 blood 1 +++ - WT sequence This study
NIH315 fluid 1 +++ - WT sequence This study
NIH320 soft tissue 1 +++ - WT sequence This study
NIH324-2 blood 1 +++ - WT sequence This study
NIH342 blood 1 +++ - WT sequence This study
NIH338 blood 1 +++ - WT sequence This study
NIH344-1 blood 1 +++ - WT sequence This study
NIH354 fascia 1 +++ - WT sequence This study
NIH361 blood 1 +++ - WT sequence This study
NIH363 blood 1 +++ - WT sequence This study
NIH380-2 blood 1 +++ - WT sequence This study
NIH392 serum 1 +++ - WT sequence This study
NIH388-2 ascites 1 +++ - WT sequence This study
NIH395-1 blood 1 +++ - WT sequence This study
NIH399-1 pleural effusion 1 +++ - WT sequence This study
NIH413 soft tissue 1 +++ - WT sequence This study
NIH415 blood 1 +++ - WT sequence This study
NIH417-3 blood 1 +++ - WT sequence This study
NIH418 soft tissue 1 +++ + WT sequence This study
NIH436 soft tissue 1 +++ - WT sequence This study
NIH444 soft tissue 1 +++ - WT sequence This study
NIH9 blood 3 mut * ++ - CsrR, GlnRPro at aa 216 CsrR, AB219966 [35]
NIH212 soft tissue 3 mut ++ + CsrR, AspRTyr at aa 60 CsrR, AB517826 This study
NIH216 fascia 3 mut ++ - CsrR, TrpRCys at aa 184 CsrR, AB517827 This study
NIH259 blood 3 mut ++ - CsrR, point mutation = stop at aa 45 CsrR, AB517839 This study
NIH300 blood 3 mut ++ + CsrR, ArgRLeu at aa 119 CsrR, AB517850 This study
NIH404 soft tissue 3 mut ++ - CsrR, 1 bp insert = stop at aa 146 CsrR, AB517867 This study
TK280 blood 3 + mut ++ CsrS, point mutation = stop at aa 131 CsrS, AB517803 This study
NIH152-3 blood 3 + mut ++ CsrS, point mutation = stop at aa 160 CsrS, AB517820 [37]
NIH249 blood 3 + mut ++ CsrS, 1 bp delete = stop at aa 35 CsrS, same as NIH156-1 This study
NIH424-1 blood 3 + mut ++ CsrS, 11 bp insert = stop at aa 39 CsrS, AB517873 This study
NIH453 effusion 3 + mut ++ CsrS, 1 bp delete = stop at aa 180 CsrS, AB517875 This study
NIH3 blood 3 ++mut + Rgg, TyrRCys at aa 31 Rgg, AB517795 [35]
NIH8 blood 3 ++mut + Rgg, IleRPhe at aa 162 Rgg, AB517798 [35]
TK3 soft tissue 3 ++mut + Rgg, TyrRCys at aa 31 Rgg, same as NIH3 This study
TK64 fascia 3 ++mut + Rgg, IleRPhe at aa 162 Rgg, same as NIH8 This study
NIH34 blood 3 ++mut + Rgg, IleRPhe at aa 162 Rgg, same as NIH8 [35]
TK1153 blood 3 ++mut + Rgg, IleRPhe at aa 162 Rgg, same as NIH8 This study
NIH357 soft tissue 3 ++mut + Rgg, PheRTyr at aa 161 Rgg, AB517856 This study
NIH1 fascia 3 mut + mut + CsrR, ArgRCys at aa 118;
Rgg, TyrRCys at aa 31
BA000034 [35]
Table 1. Cont.
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NIH No.
Strain
name
Site of
bacterial
isolation
emm
type csrR csrS rgg
Increased
SLO,
production
CsrS/CsrR and
Rgg amino acid
sequence alterations Accession No. Reference
TK283 fascia 3 mut + mut + CsrR, point mutation = stop at aa 134;
Rgg, IleRPhe at aa 162
CsrR, AB517797;
Rgg, same as NIH8
This study
NIH18 effusion 3 + mut mut + CsrS, AlaRTyr at aa 456;
Rgg, ArgRLys at aa 28
CsrS, AB517801;
Rgg, AB517802
[35]
NIH14 blood 3 +++ -W T s e q u e n c e [ 3 7 ]
NIH16 muscle 3 +++ -W T s e q u e n c e [ 3 5 ]
NIH21 blood 3 +++ -W T s e q u e n c e [ 3 5 ]
NIH158 soft tissue 3 +++ -W T s e q u e n c e [ 3 7 ]
NIH382-1 blood 3 +++ - WT sequence This study
NIH406 blood 4 mut + mut + CsrR, AspRGln at aa 53;
Rgg, ValRPhe at aa 169
CsrR, AB517868;
Rgg, AB517869
This study
NIH307 wound 4 +++ - WT sequence This study
NIH432 Joint fluid 4 +++ - WT sequence This study
NIH296 blood 6 + mut ++ CsrS, MetRIle at aa 228
and GlyRAsp at aa 357
CsrS, AB517847 This study
NIH323-1 lung 11 mut ++ + CsrR, AspRGly at aa 10 CsrR, AB517853 This study
NIH49 soft tissue 11 + mut ++ CsrS, point mutation = stop at aa 184 CsrS, AB517810 This study
NIH325-1 blood 11 + mut ++ CsrS, point mutation = stop at aa 450 CsrS, AB517854 This study
NIH50 blood 12 ++mut - Rgg, GluRAsp at aa 89 Rgg, AB517811 This study
NIH61 soft tissue 12 ++mut - Rgg, GluRAsp at aa 89 Rgg, same as NIH50 [33]
NIH109 Joint fluid 12 ++mut - Rgg, GluRAsp at aa 89 Rgg, same as NIH50 This study
NIH120 soft tissue 12 ++mut - Rgg, GluRAsp at aa 89 Rgg, same as NIH50 This study
NIH277 blood 12 ++mut - Rgg, GluRAsp at aa 89 Rgg, same as NIH50 This study
NIH383 blood 12 ++mut - Rgg, GluRAsp at aa 89 Rgg, same as NIH50 This study
NIH391 blood 12 ++mut - Rgg, GluRAsp at aa 89 Rgg, same as NIH50 This study
NIH398-2 blood 12 ++mut - Rgg, GluRAsp at aa 89 Rgg, same as NIH50 This study
NIH419 soft tissue 12 ++mut - Rgg, GluRAsp at aa 89 Rgg, same as NIH50 This study
NIH263-2 blood 12 + mut mut + CsrS, AsnRLys at aa 384;
Rgg, GluRAsp at aa 89
CsrS, AB517840; Rgg,
same as NIH50
This study
NIH43 effusion 18 mut + mut + CsrR, SerRPro at aa 154;
Rgg, CysRArg at aa 227
CsrR, AB517807; Rgg,
AB517808
This study
TK76 soft tissue 22 + mut ++ CsrS, 5 bp delete = stop at aa 407 CsrS, AB517800 This study
NIH160 blood 22 + mut ++ CsrS, 1 bp delete = stop at aa 35 CsrS, same as NIH156-1 This study
NIH172 blood 22 + mut ++ CsrS, 1 bp delete = stop at aa 35 CsrS, same as NIH156-1 This study
NIH403 blood 22 + mut ++ CsrS, point mutation = stop at aa 369 CsrS, AB517866 This study
NIH236 blood 22 + mut mut + CsrS, Change TTTTT to GAGG = stop
at aa158; Rgg, PheRLeu at aa 150
CsrS, AB517831; Rgg,
AB517832
This study
NIH98 blood 22 +++ - WT sequence This study
NIH429 blood 22 +++ - WT sequence This study
NIH35 blood 28 + mut ++ CsrS, GluRGly at aa 226 CsrS, AB517805 [35]
NIH40 blood 28 + mut ++ CsrS, GluRGly at aa 226 CsrS, same as NIH35 This study
NIH440 Joint fluid 28 + mut ++ CsrS, GluRGly at aa 226 CsrS, same as NIH35 This study
NIH422 soft tissue 28 + mut mut + CsrS, 1 bp delete = stop at aa 35;
Rgg, GluRLys at aa 84
CsrS, same as NIH156-1;
Rgg, AB517872
This study
NIH423-1 blood 28 + mut mut + CsrS, 1 bp delete = stop at aa 35;
Rgg, GluRLys at aa 84
CsrS, same as NIH156-1;
Rgg, same as NIH422
This study
NIH142-5 blood 28 +++ - WT sequence This study
NIH316 soft tissue 28 +++ - WT sequence This study
NIH200-4 blood 49 + mut * ++ CsrS, GlyRSer at aa 461 CsrS, AB517825 [34]
NIH230 blood 49 + mut * ++ CsrS, Change GTTCTTTTTT to
TCTGCATTTTC = stop at aa 39
CsrS, AB517830 [34]
NIH269 soft tissue 49 + mut * ++ CsrS, 11 bp insert = stop at aa 39 CsrS, same as NIH250-2 [38]
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NIH No.
Strain
name
Site of
bacterial
isolation
emm
type csrR csrS rgg
Increased
SLO,
production
CsrS/CsrR and
Rgg amino acid
sequence alterations Accession No. Reference
NIH346 blood 49 +++ - WT sequence This study
NIH410 soft tissue 49 +++ - WT sequence This study
NIH389 soft tissue 53 + mut ++ CsrS, 11 bp insert = stop at aa 39 CsrS, same as NIH250-2 This study
TK65 fascia 58 ++mut + Rgg, CysRPhe at aa 85 Rgg, AB517799 This study
NIH273 blood 58 mut + mut + CsrR, GlyRSer at aa 95;
Rgg, TyrRCys at aa 135
CsrR, AB517842; Rgg,
AB517843
This study
NIH301 blood 59 mut ++ + CsrR, IleRPhe at aa 30 CsrR, AB517851 This study
NIH317 blood 60 + mut ++ CsrS, point mutation = stop at aa 282 CsrS, AB517852 This study
NIH297 soft tissue 77 + mut ++ CsrS, ThrRIle at aa 266 CsrS, AB517849 This study
NIH258 soft tissue 78 +++ - WT sequence This study
TK929 blood 81 mut ++ + CsrR, ArgRSer at aa 118 CsrR, AB517804 This study
NIH156-1 blood 81 + mut ++ CsrS, 1 bp delete = stop at aa 35 CsrS, AB517821 This study
NIH268 soft tissue 81 + mut ++ CsrS, ArgRCys at aa 241 CsrS, AB517841 This study
NIH101 soft tissue 81 +++ - WT sequence This study
NIH283-1 blood 87 + mut ++ CsrS, ProRLeu at aa 16 CsrS, AB517844 This study
NIH437 blood 87 + mut ++ CsrS, SerRPro at aa 246 CsrS, AB517862 This study
NIH371 blood 87 + mut mut + CsrS, 5 bp delete = stop at aa 407;
Rgg, GluRTyr at aa 2
and IleRVal at aa 3
CsrS, same as TK76;
Rgg, AB517858
This study
NIH372 blood 87 + mut mut + CsrS, point mutation = stop at aa 193;
Rgg, AlaRThr at aa 245
CsrS, AB517859;
Rgg, AB517860
This study
NIH157 blood 89 mut ++ + CsrR, AspRTyr at aa 10 CsrR, AB517822 This study
NIH5 blood 89 + mut ++ CsrS, 5 bp insert = stop at aa 459 CsrS, AB517796 [35]
NIH58 Joint fluid 89 + mut ++ CsrS, ValRAla at aa 423 CsrS, AB517812 This study
NIH238 soft tissue 89 + mut ++ CsrS, SerRArg at aa 204 CsrS, AB517833 This study
NIH421 blood 89 + mut ++ CsrS, ArgRCys at aa 229 CsrS, AB517871 This study
NIH118 blood 89 ++mut + Rgg, AspRTyr at aa 174 Rgg, AB517818 This study
NIH345 wound 89 mut mut ++ CsrR, ArgRCys at aa 94;
CsrS, 1 bp delete = stop at aa 35
CsrR, same as NIH252-2;
CsrS, AB517855
This study
NIH250-2 blood 89 + mut mut + CsrS, 11 bp insert = stop at aa 39;
Rgg, TyrRHis at aa 135
CsrS, AB517836;
Rgg, AB517837
This study
NIH208 blood 89 +++ - WT sequence This study
NIH256 blood 89 +++ - WT sequence This study
NIH252-2 muscle 91 mut ++ + CsrR, ArgRCys at aa 94 CsrR, AB517838 This study
NIH287-1 soft tissue 112 + mut ++ CsrS, 11 bp insert = stop at aa 39 CsrS, AB517846 This study
NIH433 blood 113 + mut ++ CsrS, 3 bp delete = delete Asp at aa 470 CsrS, AB517874 This study
non-invasive
isolates
K01 pharyngitis 1 +++ - WT sequence This study
K02 pharyngitis 1 +++ - WT sequence This study
K03 pharyngitis 1 +++ - WT sequence This study
K04 pharyngitis 1 +++ - WT sequence This study
K11 pharyngitis 1 +++ - WT sequence This study
K12 pharyngitis 1 +++ - WT sequence This study
K13 pharyngitis 1 +++ - WT sequence This study
K14 pharyngitis 1 +++ - WT sequence This study
S1393 pharyngitis 1 +++ - WT sequence This study
S2582 bronchitis 1 +++ - WT sequence This study
S2638 bronchitis 1 +++ - WT sequence This study
OS02 pharyngitis 1 +++ - WT sequence This study
OS06 pharyngitis 1 +++ - WT sequence This study
OS15 pharyngitis 1 +++ - WT sequence This study
Table 1. Cont.
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NIH No.
Strain
name
Site of
bacterial
isolation
emm
type csrR csrS rgg
Increased
SLO,
production
CsrS/CsrR and
Rgg amino acid
sequence alterations Accession No. Reference
OS17 pharyngitis 1 +++ - WT sequence This study
OT3 vaginitis 1 +++ - WT sequence This study
OT7 pharyngitis 1 +++ - WT sequence This study
OT8 pharyngitis 1 +++ - WT sequence This study
OT5 tonsillitis 1 +++ - WT sequence This study
OT10 pharyngitis 1 +++ - WT sequence This study
OT11 scarlet fever 1 +++ - WT sequence This study
S1 pharyngitis 1 +++ - WT sequence This study
S4 pharyngitis 1 +++ - WT sequence This study
S13 pharyngitis 1 +++ - WT sequence This study
S14 pharyngitis 1 +++ - WT sequence This study
S15 pharyngitis 1 +++ - WT sequence This study
S16 pharyngitis 1 +++ - WT sequence This study
S25 pharyngitis 1 +++ - WT sequence This study
Se235 pharyngitis 1 +++ - WT sequence This study
F482 pharyngitis 1 +++ - WT sequence This study
Se202 tonsillitis 3 + mut ++ CsrS, ValRLeu at aa 25,
LeuRHis at aa 26
and PheRLeu at aa 28
CsrS, AB517643 This study
K22 pharyngitis 3 +++ -W T s e q u e n c e [ 3 5 ]
K23 pharyngitis 3 +++ -W T s e q u e n c e [ 3 5 ]
K24 pharyngitis 3 +++ -W T s e q u e n c e [ 3 5 ]
K25 pharyngitis 3 +++ -W T s e q u e n c e [ 3 5 ]
K31 pharyngitis 3 +++ -W T s e q u e n c e [ 3 5 ]
K32 pharyngitis 3 +++ -W T s e q u e n c e [ 3 5 ]
K33 pharyngitis 3 +++ -W T s e q u e n c e [ 3 5 ]
K34 pharyngitis 3 +++ -W T s e q u e n c e [ 3 5 ]
K35 pharyngitis 3 +++ -W T s e q u e n c e [ 3 5 ]
OT22 tonsillitis 3 +++ - WT sequence This study
OS29 pharyngitis 3 +++ - WT sequence This study
OT24 tonsillitis 3 +++ - WT sequence This study
OT28 scarlet fever 3 +++ - WT sequence This study
F495 pharyngitis 3 +++ - WT sequence This study
Se230 pharyngitis 4 +++ - WT sequence This study
F2362 pharyngitis 4 +++ - WT sequence This study
Se242 pharyngitis 6 +++ - WT sequence This study
F2446 pharyngitis 11 +++ - WT sequence This study
Se157 pharyngitis 11 +++ - WT sequence This study
Se233 pharyngitis 12 ++mut - Rgg, GluRAsp at aa 89 Rgg, same as NIH50 This study
F2369 pharyngitis 12 ++mut - Rgg, GluRAsp at aa 89 Rgg, same as NIH50 This study
StNo.205 pharyngitis 22 +++ - WT sequence This study
Se172 pharyngitis 28 +++ - WT sequence This study
F2324 pharyngitis 28 +++ - WT sequence This study
1566 pus 49 ++ * + -W T s e q u e n c e [ 3 8 ]
Kurume51 pus 49 ++ * + -W T s e q u e n c e [ 3 8 ]
KH1651 pus 49 ++ * + -W T s e q u e n c e [ 3 8 ]
S26 pharyngitis 58 +++ - WT sequence This study
STSS, streptococcal toxic shock-like syndrome; mut, mutation; SLO, streptolysin O; aa, amino acid; Ala, alanine; Arg, arginine; Asn, asparagine; Asp, aspartic acid; Cys, cysteine;
Gln,glutamine;Glu,glutamic acid;Gly,glysine;His,histidine;Ile,Isoleusine;Leu,leucine;Lys,lysine;Met,methionine;Phe,phenylalanine;Pro,proline;Ser,serine;Thr,threonine;
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primers for each virulence-associated gene. The amounts of
mRNA of protein G-related alpha2-macroglobulin-binding pro-
tein (grab), nicotine adenine dinucleotide glycohydrolase (nga),
streptodornase (phage-associated) (sdn), streptokinase (ska), and slo
in the STSS isolate of NIH34 with the rgg mutation were larger
than those of the pharyngitis isolate of K33 with the intact rgg gene
(Figure 2). On the other hand, the amounts of mRNA of the
cystein protease (speB) and streptolysin S (sagA) genes in the STSS
isolate of NIH34 were less than a half of those in the non-STSS
isolate of K33 (Figure 2). The amounts of mRNA of the IgG-
degrading protease of GAS, Mac-1-like protein (mac), C5a
peptidase (scpA), IL-8 protease (scpC), superantigen (speA), and
DNA gyrase (gyrA) genes in NIH34 were almost the same as those
in K33 (Figure 2 and data not shown). NIH34rgg
+ suppressed the
expression of virulence-associated genes to the levels found in non-
STSS isolates; further, the expression of speB and sagA genes was
increased to levels observed in non-STSS isolates (Figure 2).
Additionally, the expression pattern of the virulence genes in
K33rgg was similar to that in the STSS isolate NIH34 (Figure 2).
These findings suggest that the transcriptional expression of
multiple virulence genes, including the slo gene in GAS, was
strongly influenced by the mutation in the rgg gene.
rgg mutation is important in the pathogenesis of invasive
infections in mouse models
To elucidate the role of rgg in infections in vivo, we used GAS
intraperitoneal injections to compare the lethality and histopathol-
ogy of NIH34 with that of the K33 strain in a mouse model. The
NIH34 strain showed significantly higher lethality than the K33
strain (p=0.00027) (Figure 3A). Introduction of the rgg mutation in
the K33 strain (K33rgg) resulted in higher lethality among infected
mice than the K33 strain (p=0.00067) and exerted a level of
lethality similar to NIH34. The NIH34 strain into which an intact
rgg gene (NIH34rgg
+) had been introduced exhibited less lethality
than the NIH34 strain (p=0.0000097) and possessed the same level
of lethality as the K33 strain. We confirmed that bacteria isolated
from kidney or liver of infected mice at day 6 retained the mutation
(data not shown). Therefore, the mutation of the rgg gene in the
STSS isolatescontributed toenhancedlethalityinthe mousemodel.
Histopathological examination of mice infected with NIH34 or
K33rgg strains was carried out. Scattered multiple inflammatory foci
containing bacterial colonies were observed in the kidney. The foci
were accompanied with neutrophil infiltration, cell debris and
hyalinization (Figure 3B). In contrast, no significant pathological
change was observed in mice inoculatedwiththe K33or NIH34rgg
+
strains (Figure 3B). In another mouse model of soft-tissue infections,
subcutaneous infection with NIH34 or K33rgg resulted in sig-
nificantlylargerlesionsascomparedtotheinfectionwith NIH34rgg
+
orK33(p,0.01)(Figure3C).Bacteriawereisolatedfrom spleen and
kidney after the subcutaneous infection of the rgg mutants but not
the intact rgg strains. We confirmed that bacteria isolated from
lesions retained the mutation (data not shown).This showed that
subcutaneous inoculation of mice led to the systemic spreading in
the rgg mutant. These results suggest that the rgg-mutated strains
isolated from STSS patients are more virulent in vivo than strains
from patients with non-invasive infections, and that the increase in
virulence in vivo is canceled by introducing an intact rgg gene.
Mechanism of the resistance of rgg mutants to killing by
human neutrophils
In our previous study, using the Transwell system, we showed
that SLO, which causes necrosis in neutrophils, and an IL-8
protease of ScpC are important for bacterial resistance to killing by
Trp, tryptophan; Tyr, Tyrosine; Val, valine; WT, wild type.
+in csrS,csrR,and rgg,thesamesequenceasthewildtypedgeneofSF370.+inSLO,enhancedproduction.–inSLO,thesameamountasthewildstrainofSF370.AccessionNo.
deposited in DDBJ.
*: Each gene of these isolates was presented in previous publications [2,5].
doi:10.1371/journal.ppat.1000832.t001
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Table 2. Mutation frequency in the csrS/csrR and rgg genes.
No. of strains with mutation(s) in gene(s)(%)
Isolates from
patients with: csrS csrR rgg csrS+csrR csrS+rgg csrR+rgg csrS+csrR+rgg none Total
STSS Total 46 (28.0) 13 (7.9) 27(16.5) 2 (1.2) 9 (5.5) 6 (3.7) 0 (0) 61 (37.2) 164 (100)
SLO (+)4 6 9
b 18 2 9 6 0 1 91
Non-functional mutation 46 (28.0)
a 13 (7.9)
b 18 (11.0)
c 2 (1.2) 9 (5.5) 6 (3.7) 0 (0) 0 (0) 94 (57.3)
Non-invasive
diseases
Total 1 (1.7) 0 (0) 2 (3.4) 0 (0) 0 (0) 0 (0) 0 (0) 56 (94.9) 59 (100)
SLO (+)1 0 0 0 0 0 0 0 1
Non-functional mutation 1 (1.7)
a 0( 0 )
b 0( 0 )
c 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.7)
acsrS mutation affects significantly the expression of slo gene [18], and the mutant shows mucoid colony because the expression of the capsule synthesis operon is
increased [4,39]. The function of CsrS was determined by colony morphology and by increase of SLO production.
bcsrR mutation does not affect significantly the expression of slo gene [18]. The cause of SLO increase in the 9 csrR mutants was described in the section of Discussion.
The csrR mutant shows mucoid colony because the expression of the capsule synthesis operon is increased [4,39]. The function of csrR was determined by colony
morphology.
crgg mutation affects significantly the production of slo gene [Figure 1, [16]] and SpeB [14,16–17]. The function of Rgg was determined by the increase of SLO
production and the decrease of SpeB production.
doi:10.1371/journal.ppat.1000832.t002
Highly Frequent Mutations in STSS Isolates
PLoS Pathogens | www.plospathogens.org 8 April 2010 | Volume 6 | Issue 4 | e1000832neutrophils [2]. Here, we examined the effect of rgg mutation on
resistance to killing by neutrophils. As shown in Figure 4A, the
migration ability of human neutrophils in response to chemokine
IL-8 did not significantly differ between K33 and K33rgg or
between NIH34 and NIH34rgg
+. Furthermore, the scpC mutation
in the NIH34 strain did not have a significant influence on the
migration of human neutrophils, compared to the csrS mutation, as
previously reported (Figure 4A). This finding is in accordance with
the less influence of ScpC expression in the rgg mutation (Figure 2).
Collectively, the mutation of the rgg gene had little influence on the
migration of human neutrophils in response to IL-8. As previously
reported [2], migrated neutrophils may be killed by the STSS
GAS isolates via enhanced SLO production, and therefore we
examined this possibility. Human neutrophils were efficiently
killed by the rgg-mutated strains (NIH34 and K33rgg), whereas
strains with the intact rgg gene (K33 and NIH34rgg
+) did not cause
obvious impairment of neutrophils (Figure 4B). In the slo-deficient
mutant, the ability to kill neutrophils was abolished. Nicotine
adenine dinucleotide glycohydrolase (Nga) is a cytotoxic protein
secreted through the SLO complex [15]. Based on the results that
the nga expression was negatively regulated by the rgg gene
(Figure 2), we examined the lethal activity of the nga mutant
against neutrophils. The neutrophil-killing activity was significant-
ly decreased in an nga-deficient mutant (NIH34nga), but to a lesser
extent as compared to the activity of NIH34slo. Therefore,
these findings strongly suggest that SLO is a factor essential for
neutrophil-killing activity in rgg-mutated emm3 STSS isolates, and
that Nga partially influences the neutrophil-killing activity.
Comparison of virulence between the csrS and rgg
mutations
In our previous study, a csrS mutation in the emm49-genotyped
strains was a key to the onset of severe invasive streptococcal
infections [2]. The csrS mutant showed higher lethality in a mouse
model and more efficiently killed human neutrophils than the non-
mutated strain [2]. Therefore, we next compared the effect of the
mutation in the csrS gene with that in the rgg gene, in terms of in
vivo virulence in lethality and impairment of neutrophil function in
vitro. Intraperitoneal infection of mice with the csrS mutant
(K33csrS) caused earlier death and higher lethality than did
infection with the rgg mutant (K33rgg)( p=0.017) (Figure 3A).
Furthermore, K33csrS strains decreased the migration ability of
neutrophils in response to IL-8, and they induced necrosis of
migrated neutrophils to a greater degree than did the rgg mutants
(Figures 4A, B). These and the aforementioned results suggest that
the rgg mutant can escape being killed by neutrophils only because
of the SLO function, and not because of ScpC, whereas both SLO
and ScpC in the csrS mutant contribute to the escape. This
suggests that the csrS mutant may be more virulent in systemic
infections than the rgg mutant, owing to its ability to up-regulate
more virulence factors such as ScpC (Figures 2 and 3A,B).
Table 3. Amino acid difference in comparison with intact ORF of SF370.
Isolates Strain name SPs0322 (CodY) SPs1615 (CsrR) SPs1742 (Rgg) CsrS
Non-STSS isolates C500 ++ + +
OT22 ++ + +
K33 ++ + +
STSS isolates NIH1 - - - +
NIH3 - + - +
NIH8 ++ - +
NIH34 ++ - +
(+): the same as the intact ORF of SF370 (accession No. AE004092)).
(-): difference from the intact ORF.
doi:10.1371/journal.ppat.1000832.t003
Figure 1. More SLO is secreted in STSS isolates than in isolates from non-invasive infections. The supernatants from an overnight culture
(OD600=1.0) of emm3 S. pyogenes clinical isolates (non-STSS: C500, OT22, and K33; STSS: NIH1, NIH3, NIH8, NIH34, NIH152, NIH249, NIH327, and
NIH352; non-STSS isolates with the mutated rgg gene: OT22rgg and K33rgg; STSS isolates complemented with the intact rgg gene: NIH8rgg
+ and
NIH34rgg
+) were concentrated with trichloroacetic acid, and 5 ml of each sample was analyzed by western blotting with rabbit anti-SLO polyclonal
antibody. Representative data of two independent experiments are shown.
doi:10.1371/journal.ppat.1000832.g001
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STSS clinical isolates
In this study, we found that there are mutations in the rgg gene
or the csrS/csrR genes in STSS clinical isolates. We sequenced the
rgg gene in strains isolated from sterile sites of STSS patients and
found that 42 of 164 (25.6%) isolates carried some mutations
(deletion, point mutation, or insertion) in the rgg gene. To
determine whether these mutations contributed to a loss of Rgg
function, we examined the level of SLO and SpeB [14] secretion
and compared it with that in non-STSS isolates because
overproduction of SLO [This study, 16] and less secretion of
SpeB are also reported in the rgg mutation [14,16–17]. We defined
these phenotyped isolates as Rgg non-functional mutants. In 33 of
42 isolates, SLO production had increased and SpeB production
had decreased (Tables 1 and 2 and data not shown). All of
remaining nine rgg mutants (strains with mutation only in rgg)
showing no increase of SLO expression were emm12-genotyped
strains and had a mutation at the same position in comparison
with other non-invasive strains. This mutation was synonymous in
the level of amino acid, so we defined the mutants are functional as
shown in Table 2. Collectively, 11.0%, 28.0%, 7.9%, 1.2%, 5.5%,
and 3.7% of the 164 STSS clinical isolates carried non-functional
mutations in the rgg, csrS, csrR, both csrS and csrR, both csrS and rgg,
and both csrR and rgg genes, respectively, so that a total of 57.3%
of the STSS isolates carried mutations in one or more of these
negative regulator genes (Tables 1 and 2). On the other hand, the
frequency of mutations in these genes was very low (1.7%) in non-
invasive isolates (Tables 1 and 2). Therefore, the incidence of
mutations in these genes is higher in STSS isolates than in non-
invasive isolates (p,0.01 by x
2 analysis). This finding suggests that
mutations in the csrS/csrR genes or the rgg gene are crucial factors
causing severe invasive infections, such as STSS.
Discussion
Since the late 1980s, STSS caused by S. pyogenes has become a
serious health problem in both developed and developing
countries. In this study, we found a high frequency of mutations
of negative regulators in STSS clinical isolates. The rgg mutant
killed human neutrophils, impaired multiple organs, and enhanced
lethality in the mouse model, similar to the csrS mutant. These
findings suggest that the impairment of negative regulators of S.
pyogenes virulence genes induces neutrophil incompetence and
subsequent STSS infection. This study is the first to show that
clinical S. pyogenes isolates from STSS patients have mutations in
one or more of genes––rgg, csrS, and csrR––which are involved in
the negative regulation of multiple virulence genes.
In our previous study, we found mutations in the csrS/csrR genes
of 5 emm49 strains isolated from patients with severe invasive
infections [2]. In the present study, we further examined whether
STSS isolates other than the emm49 genotype possess mutations in
the csrS and csrR genes: 46.3% of the STSS isolates including
various emm genotypes had non-functional mutations in one or
more of the csrS/csrR genes. This finding suggests that mutations in
the csrS/csrR genes are commonly recognized in STSS clinical
isolates with various emm genotypes.
We have shown that the amount of SLO protein produced in
STSS isolates is greater than that in non-STSS isolates, and that
this effect is due to mutations in both the rgg and csrS genes of the
isolates. The loss of function incurred by the mutation in the rgg
gene in emm3-genotyped S. pyogenes affected the regulatory network
of the virulence-associated genes; hence, the mutated strains could
resist killing by neutrophils and caused damage to various organs
in the mouse models. Therefore, the mutated emm3-genotyped S.
pyogenes strains may potentially cause severe infections such as
STSS in humans. Hollands et al. [14] reported that a mutation of
the rgg (ropB) gene reduces M1T1 group A streptococcal virulence.
We examined the contribution of Rgg to the pathogenesis
of systemic infections by using a clinical emm1-genotyped STSS
isolate, NIH186, and an emm1-genotyped pharyngitis isolate,
Se235. NIH186 and Se235rgg, both of which had a mutation in the
rgg gene, showed higher lethality than NIH186rgg
+ and Se235, in
both of which the rgg gene is intact (data not shown). The rgg
mutants impaired neutrophils to a greater extent than the rgg-
intact strains did (Figure S1); this finding suggests that rgg mutants
are more virulent than rgg-intact strains, in the emm1 genotype.
Therefore, the discrepancy between the finding in this study and
that of Hollands et al. [14] may be attributed to modified
regulation of SLO expression in rgg-mutated isolate in the latter,
but not downregulation of speB and sagA operons.
Rgg is reported to regulate the transcription of many virulence-
associated genes in S. pyogenes [10–13], and its regulatory profile
varies among strains used [16–17]. Nevertheless, up-regulation of
the slo, nga and ska genes and down-regulation of the speB gene
are commonly found in the rgg mutation of emm3-genotyped
isolates (Figure 2) and of M49 serotyped-strains, NZ131 and
CS101 [16–17], suggesting they are the Rgg core regulon of GAS
strains.
In recent studies, it has been reported that expression of the rgg
gene is positively regulated by CsrS [4], while it is negatively
regulated by CsrR [16]. Expression of the slo gene is enhanced in
the csrS mutant (Figure 2) [2,4], but not in the csrR mutant [18]. In
this study, the expression of the slo gene was enhanced in the rgg
mutant (Figure 2), suggesting that the enhancement of the slo gene
may serve as the same regulatory pathway as the effect of the csrS
mutation. These findings suggest that CsrS affects the Rgg regulon
as well as the CsrR regulon (Figure 5); in the csrS mutant, CsrR is
not phosphorylated by CsrS, and Rgg expression is suppressed.
It has been reported that the csrR null-mutation does not affect
the expression of SLO [18]. However, Trevin ˜o et al. [19] reported
that SLO production increases as a result of a csrR mutation in
which histidine replaces arginine at position 119 of the CsrR
protein; however the protein retained DNA-binding activity. The
strains carrying such a kind of mutation are phenotypically
identical to the csrS mutants [19]. Nine csrR mutants in this study
showed increased SLO production (Tables 1 and 2), 2 (NIH136
and NIH300) of which had an amino acid replacement at position
119 of CsrR protein. Other 7 isolates showed mutation in the
N-terminal amino acid of CsrR, but the exact mechanism of the
CsrR mutant remains to be solved.
The csrS/csrR and rgg genes negatively regulate various virulence
genes; however, they regulate different virulence genes. The slo,
Figure 2. Mutation of the rgg gene influences expression of virulence-associated genes. The expression of virulence-associated genes in
non-STSS, STSS GAS isolates, and strains into which an intact gene or mutant rgg or mutant csrS gene had been introduced was analyzed by RT-PCR;
columns represent the relative mRNA expression levels of virulence-associated genes of each strain: nicotine adenine dinucleotide glycohydrolase
(nga), streptolysin O (slo), streptokinase (ska), protein G-related alpha2-macroglobulin-binding protein (grab), streptodornase (phage-associated)
(sdn), streptolysin S (sagA), streptococcal pyrogenic endotoxin (speB), and IL-8 protease (scpC). The expression level of K33 strain is shown as 1. Values
are means 6 SD (n=4).
doi:10.1371/journal.ppat.1000832.g002
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mice infected with each strain. Mice were intraperitoneally inoculated with 1610
7 CFU of each GAS, and mouse survival was observed for 7 days post-
infection.Mortalitydifferenceswerestatisticallysignificant(P,0.01),asdeterminedbyalog-ranktest.Survivalcurves weregeneratedfrom3independent
experiments using a total of 10–16 ddY mice for each strain. (B) Histopathological changes in the kidneys of mice infected with GAS. Tissuewas extracted
at 24 h after the intraperitoneal injection of GAS (1610
7 CFU). The black arrows indicate clusters of bacteria with filtrated inflammatory cells. The triangle
headsindicatefibrousdebris.(C)LesionareasofsubcutaneousinfectioninhairlessmiceinjectedwithGAS.1610
7 CFUin100 mLsuspensionofGASinPBS
was injected subcutaneously, and the lesion area and body weight were measured each day after infection. The peak values are shown as means 6 SD
(n=5). *The skin-lesion area in rgg mutant strains-infected mice was significantly larger than that in rgg intact strains (p,0.05), as estimated by ANOVA.
doi:10.1371/journal.ppat.1000832.g003
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Rgg. The grab gene is negatively regulated by Rgg, while the mac,
scpA, and scpC genes are negatively regulated by CsrS [2] (Figure 2).
Thus, in terms of impairing neutrophil function, the csrS mutant
inhibits the migration of neutrophils due to the destruction of IL-8
by the increased expression of scpC (Figure 5) [2]; meanwhile, the
rgg mutant does not significantly affect the expression of scpC.O n
the other hand, since both rgg and csrS genes negatively regulate
the expression of slo, infections with these mutants result in
damage of neutrophils due to the increased production of SLO in
the foci. This may explain why neutrophils are observed
histopathologically in some cases of severe invasive infection, but
are not in others. Indeed, our mouse model shows that neutrophils
clustered around the foci of bacteria in the kidney infected by the
rgg mutant (Figure 3B) but not by the csrS mutant [2].
The slo, nga, and ska genes are negatively regulated by both CsrS
and Rgg [2] (Figure 2). We previously reported that SLO is an
important virulence factor for the necrosis of neutrophils, which
leads to higher lethality of infected mice [2]. Nucleosidase
(NADase), which is encoded by the nga gene, contributes to severe
invasive infections by GAS in the murine model of infection [20].
Streptokinase, which is encoded by the ska gene, has an important
role in GAS invasion and proliferation [21]. STSS isolates
carrying mutations in the csrS gene and/or the rgg gene commonly
increased the expression of these genes [2; this study]. Thus,
overproduction of these factors in the mutants could cooperatively
contribute to increased virulence, thus causing the onset of STSS.
Notably, the mutation frequency of these genes in STSS isolates
(57.3%) was much higher than that in non-invasive isolates (1.7%).
These results suggest that mutations in the negative regulators of
various virulence genes are important to the STSS onset.
However, 42.7% of the STSS isolates did not have mutations in
the csrS/csrR or rgg genes. Such strains may have mutations in
other various other two-component regulatory systems or
regulators in the S. pyogenes genome [22], which would be the
focus of our research. We could not exclude the possibility that
clinical severity of infection by strains lacking any mutations in the
three genes depends on host factors, and not on bacterial factors.
Specific human leukocyte antigen class II haplotypes are
associated with a risk of disease severity [23], and the importance
of both host and environmental factors has been reported [24].
In the mouse model, the csrS mutant (K33csrS) showed higher
lethality than the rgg mutant. However, in the present study, the
mortality rate of STSS patients infected with the rgg mutant
was 60.9%, while that of patients infected with the csrS mutant
was 47.2% (data not shown). These findings suggest that the
rgg mutant also causes high lethality in humans, which may
indicate differences in disease severity between humans and mice.
Streptokinase is highly specific for human plasminogen, exhi-
biting little or no activity to those of other animal species [25].
Figure 4. Effect of rgg and other mutations on migration and survival of human neutrophils. (A) The effect of human neutrophil
migration in response to IL-8 by various GAS strains (K33, NIH34, and their rgg, slo, scpC, nga, and csrS mutants) was analyzed using a Transwell
system and flow cytometry. About 62% of applied human neutrophils migrated through the Transwell, under the conditions of IL-8 addition. Values
shown are means 6 SD (n=3). *p,0.05, as estimated by ANOVA. The results shown are representative of one of five individual experiments, all of
which had similar results. (B) The viability of human neutrophils in the lower wells of a Transwell system, after migration in response to IL-8. The
migrated human neutrophils were bought into contact with various GAS strains (K33, NIH34, and their rgg, slo, scpC, nga, and csrS mutants), and the
remaining viable neutrophils were counted. Values shown are means 6 SD (n=3). *p,0.05, as estimated by ANOVA.
doi:10.1371/journal.ppat.1000832.g004
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cases of infection with the rgg mutant.
Collectively, we showed that mutations of negative regulators that
result in the overproduction of multiple virulence factors are
important to the onset of severe invasive infections such as STSS.
Recently, it has been reported that community-associated methicil-
lin-resistant Staphylococcus aureus (CA-MRSA) causes severe invasive
infections, resulting in NF or even death [26,27]. The enhanced
virulence of CA-MRSA has been linked to an overproduction of
leukolytic peptides, phenol-soluble modulins (PSMs) [28,29]. The
production of PSMs is regulated under the strict control of agr [29].
The change of expression of the agr regulator results in increased
expression of virulence factors and increased virulence. Severe
invasive infections are caused not only by S. pyogenes but also by other
bacteriasuchas otherStreptococcus,Staphylococcusaureus, Vibriovulnificus,
and Aeromonas spp. Such severe invasive infections may be caused by
the coordinated overexpression of multiple virulence factors that are
affected by the global regulatory network.
Methods
Ethic statement
This study complies with the guidelines of the declaration of
Helsinki. This study protocol was approved by the institutional
individual ethics committees for the use of human subjects (the
National Institute of Infectious Diseases Ethic Review Board for
Human Subjects) and the animal experiments (the National
Institute of Infectious Diseases Animal Experiments Committee).
Written informed consent was obtained from all study participants
or their legal guardians for the patients who died. All clinical
samples and healthy human neutrophils were stripped of personal
identifiers not necessary for this study. All animal experiments
were performed according to the Guide for animal experiments
performed at National Institute of Infectious Diseases, Japan.
Bacterial strains and culture conditions
The S. pyogenes strains and plasmids used in this study are
described in Tables 1 and S1. The STSS criteria in this study are
based on those proposed by the Working Group on Severe
Streptococcal Infections [8]. The clinical isolates used were
isolated from sterile sites of patients with STSS (164 isolates; age
0–99 years) and from non-sterile sites of patients with non-invasive
infections (59 isolates; ages 1–67 years). The isolates from STSS
and non-invasive infections were collected by the Working Group
for Beta-hemolytic Streptococci in Japan, as previously reported
[30]. Escherichia coli DH5a was used as a host for plasmid
construction and was grown in a Luria-Bertani liquid medium
with shaking or on agar plates at 37uC. S. pyogenes was cultured in
Todd-Hewitt broth supplemented with 0.5% yeast extract (THY
medium) without agitation or on tryptic soy agar supplemented
with 5% sheep blood. Cultures were grown at 37uC in a 5% CO2
atmosphere. When required, antibiotics were added to the
medium at the following final concentrations: erythromycin,
300 mg/mL for E. coli and 1 mg/mL for S. pyogenes; and
spectinomycin (Sp), 25 mg/mL for each of E. coli and S. pyogenes.
The growth of S. pyogenes was turbidimetrically monitored at
600 nm, using a MiniPhoto 518R (Taitec, Tokyo, Japan).
DNA sequencing and data deposit
The nucleotide sequences of the csrS, csrR, and rgg genes were
determined by automated sequencers, i.e., an Applied Biosystems
3130xl Genetic Analyzer and an Applied Biosystems 3130 Genetic
Analyzer (both Applied Biosystems, Tokyo, Japan). Sequencing
data were deposited in the DNA Data Bank of Japan (DDBJ).
Animals
Male five to six-week-old outbred ddY and hairless mice were
purchased from SLC (Shizuoka, Japan) and maintained in specific
Figure 5. Schema of regulatory network and its dysfunction in STSS isolates leading to host evasion. CsrS phosphorylates CsrR, and the
CsrR represses expression of a number of virulence genes including rgg and scpC [18]. CsrS also positively regulates the expression of rgg [4], which
suppresses slo gene expression (Figure 2). The rgg mutation causes an overexpression of SLO, which kills neutrophils, but has no influence on ScpC
expression. In the csrR mutant, overproduced ScpC inhibits the migration of neutrophils, and upregulated Rgg reduces the slo gene expression. In the
csrS mutant, inactive form of CsrR leads to the overproduction of ScpC, which inhibits the migration of neutrophils, and decrease of Rgg leads to the
overproduction of SLO, which kills neutrophils.
doi:10.1371/journal.ppat.1000832.g005
Highly Frequent Mutations in STSS Isolates
PLoS Pathogens | www.plospathogens.org 14 April 2010 | Volume 6 | Issue 4 | e1000832pathogen-free (SPF) conditions. All animal experiments were
performed according to the guidelines of the Ethics Review
Committee of Animal Experiments of the National Institute of
Infectious Diseases, Japan.
Construction of deletion or deficient mutants
(i) Construction of the rgg mutant. A 692-bp DNA
fragment containing the internal region of rgg was amplified
from the NIH34 (for emm3) and NIH186 (for emm1) chromosomal
DNA, using the primers of rgg-del1 and rgg-del2 (Table S3). The
PCR products were digested by BamHI and EcoRI. This fragment
was then cloned into the integration shuttle vector pSF152 [31] to
create the plasmid pSF152rgg3 and pSF152rgg1, respectively,
which was then used for the chromosomal inactivation of the rgg
gene, as described previously [31]. The inactivated mutant strains
K33rgg, OT22rgg,S 1 rgg, Se235rgg and F482rgg (rgg::aad9 Sp
r) were
then selected by using spectinomycin-containing agar plates.
Deficiency of the native rgg gene was verified by PCR.
(ii) Construction of the csrS mutant. A 930-bp DNA
fragment containing the internal region of csrS was amplified from
the K33 chromosomal DNA, using the primers of csrS-def1 and
csrS-def2 (Table S3). The PCR products were digested by BamHI
and EcoRI. This fragment was then cloned into the integration
shuttle vector pSF152 to create the plasmid pSF152csrS, which was
then used to create K33csrS, as described above.
(iii) Construction of the slo mutant. A 1,061-bp DNA
fragment containing the internal region of slo was amplified from
the NIH34 chromosomal DNA, using the primers of slo-del3 and
slo-del4 (Table S3). The PCR products were digested by BamHI
and EcoRI. This fragment was then cloned into the integration
shuttle vector pSF152 to create the plasmid pSF152slo, which was
then used to create NIH34slo, as described above.
(iv) Construction of the scpC mutant. A 1,240-bp DNA
fragment containing the internal region of scpC was amplified from
the NIH34 chromosomal DNA, using the primers of scpC-del5 and
scpC-del6 (Table S3). The PCR products were digested by BamHI
and EcoRI. This fragment was then cloned into the integration
shuttle vector pSF152 to create the plasmid pSF152scpC, which was
then used to create NIH34scpC, as described above.
(v) Construction of the sdn mutant. A 693-bp DNA
fragment containing the internal region of sdn was amplified from
the NIH34 chromosomal DNA, using the primers of sdn-def3 and
sdn-def2 (Table S3). The PCR products were digested by BamHI
and EcoRI. This fragment was then cloned into the integration
shuttle vector pSF152 to create the plasmid pSF152sdn, which was
then used to create NIH34sdn, as described above.
(vi) Construction of the nga mutants. A 1,071-bp DNA
fragment containing the 59 terminal of nga and the adjacent
upstream chromosomal DNA was amplified from the NIH34
chromosomal DNA, using the primers of ngadel1 and ngadel2
(Table S3); additionally, a 775-bp fragment containing the 39
terminal of nga and the adjacent downstream chromosomal DNA
was amplified from the NIH34 chromosomal DNA, using the
primers of ngadel3 and ngadel4 (Table S3). These two PCR
products were digested by BamHI and EcoRI and by EcoRI and PstI,
respectively. The digested fragments were cloned into the
erythromycin-resistant and temperature-sensitive shuttle vector
pJRS233 [32], to create the plasmid pJRSDnga. This plasmid was
then introduced into the strain NIH34 by electroporation, and
transformants were selected on erythromycin agar plates at 30uC.
To create an integration of pJRSDnga with the chromosome,
transformants were grown at 39uC and selected with erythromycin.
Replacement of the native nga gene by the nga-deleted mutant allele
was verified by PCR,and the resultant strainwasnamed NIH34nga.
Construction of strains integrating the intact rgg gene
The replacement of a mutated rgg gene by an intact rgg gene was
performed by allelic recombination. Specifically, the chromosomal
DNA derived from the GAS strains K33 (for emm3) and F482
(for emm1) was purified and used as a template for the PCR
amplification of the intact rgg gene. The primers used were 59-
GGGGATCCTTATGGCTATATCATAGCTG-39 (sense) and
59-GGGAATTCTGTTGAGATAAACTACACC-39 (antisense).
The PCR fragment was ligated into the plasmid pSF152, and
the resultant plasmids pSFrgg3+ (for emm3) and pSFrgg1+ (for emm1)
were used for chromosomal integration into the mutated rgg gene
of isolates from STSS patients, as described previously [31]. The
integrated strains (Sp
r) were then selected by using spectinomycin
(Sp)-containing agar plates. Integration of the intact rgg gene was
confirmed by PCR.
Western blotting
A total of 1 mL of the supernatant of an overnight bacterial
culture (OD600=1.0) was passed through a 0.45-mm pore size
membrane filter (Nippon Millipore, Tokyo, Japan), to remove the
remaining cells. Proteins in the resulting cell-free supernatant were
precipitated with 10% trichloroacetic acid and resuspended in a
sample loading buffer containing a saturated Tris base. Samples
were heated at 100uC for 3 min and separated on sodium dodecyl
sulfate (SDS)–12.5% polyacrylamide gels. To detect SLO, the
proteins on the gels were electrophoretically transferred onto
a PVDF membrane. The membrane was blocked with 5%
nonfat milk +0.2% Tween-20 and reacted with primary anti-SLO
polyclonal antibody (American Research Products, Belmont, MA,
USA), secondary antibody peroxidase-conjugated anti-rabbit Ig
(GE Healthcare, Tokyo, Japan), and an ECL Plus Western
blotting Detection System (GE Healthcare).
Complete-genome comparisons
Complete-genome comparisons were performed with an array-
based service (CGS) provided by NimbleGen Systems Inc.
(Madison, WI, USA) [9]. The reference genome sequence used
in the microarray was that of S. pyogenes SSI-1 (GenBank accession
No. BA000034).
Quantitative RT-PCR analysis
Total RNA was extracted from bacterial cells using the RNeasy
Protect Bacteria Mini Kit (QIAGEN, Tokyo, Japan), according to
the manufacturer’s instructions. Complementary DNA synthesis
was performed with the PrimeScript RT reagent kit (Perfect Real
Time) (Takara Bio, Otsu, Japan), also following the manufacturer’s
instructions. Transcript levels were determined using the ABI
PRISM Sequence Detection System 7000 (Applied Biosystems)
and Premix Ex Taq (Perfect Real Time) (Takara). For real-time
amplification, the template was equivalent to 5 ng of total RNA.
Measurements were performed in triplicate; a reverse-transcrip-
tion-negative blank of each sample and a no-template blank served
as negative controls. The primers and probes used are listed in
Table S4.
GAS infection in a mouse model
GAS was grown to late-log phase (OD600=0.620.8) at 37uC
in a 5% CO2 atmosphere, pelleted by centrifugation, washed twice
with sterile phosphate-buffered saline (PBS), suspended in sterile
PBS. A total of 1610
7 CFU of GAS suspended in 0.5 mL of PBS
was injected intraperitoneally into five to six-week-old ddY
outbred male mice (10–16 mice/GAS isolate). The number of
surviving mice was compared statistically, using the Kaplan-Meier
Highly Frequent Mutations in STSS Isolates
PLoS Pathogens | www.plospathogens.org 15 April 2010 | Volume 6 | Issue 4 | e1000832log-rank test. For the subcutaneous infection model, male hairless
mice Hos:Hr-1 were injected with 1610
7 CFU of GAS in a 100-ml
suspension of GAS in PBS. The lesion area was measured daily
and analyzed. Dissemination in kidney and spleen of GAS was
evaluated by colony counting at day 7 post-infection.
Histopathological examination
For histopathological analysis, the tissues from GAS-infected
mice were directly fixed in 10% neutral-buffered formalin,
embedded in paraffin, sectioned and stained with hematoxylin
and eosin (H&E).
Isolation of human neutrophils
Human neutrophils were isolated from the venous blood of five
healthy volunteers, in accordance with a protocol approved by the
Institutional Review Board for Human Subjects, National Institute
of Infectious Diseases [2]. This study complies with the guidelines
of the declaration of Helsinki.
Migration assay
Chemotaxis assays were performed as previously described [2].
Briefly, 5610
5 neutrophils in Roswell Park Memorial Institute
(RPMI) medium containing 25 mM HEPES and 1% FCS in
Transwell inserts (3-mm pore size; Coaster, Corning, NY, USA)
were placed in 24-well plates containing 600 ml medium or 100 nM
interleukin (IL)-8 solution (Pertec, London, UK); the plates were
then incubated with or without 5610
6 bacteria for 1 h at 37uC, in
advance of the assay. After 1 h of incubation, cells in the lower wells
were collectedand 10
4 10-mm microsphere beads (Polysciences Inc.,
Warrington, MA, USA) were added. Cells were stained with
propidiumiodine(Sigma,StLouis,MO,USA)forflowcytometryto
quantify the viable neutrophils; analysis was performed, using the
FACS Calibur (BD Biosciences, San Jose, CA, USA).
Accession numbers
The DNA Data Bank of Japan (DDBJ) (http://www.ddbj.nig.
ac.jp/index-e.html) accession numbers for the genes and gene
products discussed in this paper are: TK283 csrR locus -
AB517797; TK929 csrR locus - AB517804; NIH43 csrR locus -
AB517807; NIH75 csrR locus - AB517814; NIH136 csrR locus -
AB517819; NIH157 csrR locus - AB517822; NIH212 csrR locus -
AB517826; NIH216 csrR locus -AB517827; NIH252-2 csrR locus -
AB517838; NIH259 csrR locus - AB517839; NIH273 csrR locus -
AB517842; NIH300 csrR locus - AB517850; NIH301 csrR locus -
AB517851; NIH323-1 csrR locus - AB517853; NIH381-1 csrR
locus - AB517863; NIH404 csrR locus - AB517867; NIH406 csrR
locus - AB517868; NIH447 csrR locus - AB517877; NIH5 csrS
locus - AB517796; TK76 csrS locus - AB517800; NIH18 csrS locus
- AB517801; TK280 csrS locus - AB517803; NIH35 csrS locus -
AB517805; NIH44 csrS locus - AB517809; NIH49 csrS locus -
AB517810; NIH55 csrS locus - AB517812; NIH75 csrS locus -
AB517815; NIH102 csrS locus - AB517817; NIH152-3 csrS locus -
AB517820; NIH156-1 csrS locus - AB517821; NIH205 csrS locus -
AB517823; NIH200-4 csrS locus - AB517825; NIH220-1 csrS locus
- AB517828; NIH222 csrS locus – AB517829; NIH230 csrS locus -
AB517830; NIH236 csrS locus - AB517831; NIH238 csrS locus -
AB517833; NIH243 csrS locus - AB517834; NIH253-1 csrS locus -
AB517835; NIH250-2 csrS locus - AB517836; NIH263-2 csrS locus
- AB517840; NIH268 csrS locus - AB517841; NIH283-1 csrS locus
- AB517844; NIH286 csrS locus - AB517845; NIH287-1 csrS locus
- AB517846; NIH296 csrS locus - AB517847; NIH297 csrS locus -
AB517849; NIH317 csrS locus - AB517852; NIH325-1 csrS locus -
AB517854; NIH345 csrS locus - AB517855; NIH372 csrS locus -
AB517859; NIH437 csrS locus - AB517862; NIH403 csrS locus -
AB517866; NIH421 csrS locus - AB517871; NIH424-1 csrS locus -
AB517873; NIH433 csrS locus - AB517874; NIH453 csrS locus -
AB517875; Se202 csrS locus - AB517643; NIH3 rgg locus -
AB517795; NIH8 rgg locus - AB517798; TK65 rgg locus -
AB517799; NIH18 rgg locus - AB517802; TK1097 rgg locus -
AB517806; NIH43 rgg locus - AB517808; NIH50 rgg locus -
AB517811; NIH60 rgg locus - AB517813; NIH91 rgg locus -
AB517816; NIH118 rgg locus - AB517818; NIH186 rgg locus -
AB517824; NIH236 rgg locus - AB517832; NIH250.2 rgg locus -
AB517837; NIH273 rgg locus - AB517843; NIH293 rgg locus -
AB517848; NIH357 rgg locus - AB517856; NIH366 rgg locus -
AB517857; NIH371 rgg locus - AB517858; NIH372 rgg locus -
AB517860; NIH374-2 rgg locus - AB517861; NIH381-1 rgg locus -
AB517864; NIH390 rgg locus - AB517865; NIH406 rgg locus -
AB517869; NIH409 rgg locus - AB517870; NIH422 rgg locus -
AB517872; NIH445 rgg locus - AB517876.
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Figure S1 Effect of rgg mutation of emm1-genotyped S. pyogenes on
survival of human neutrophils. Human neutrophils migrated in the
lower wells of a Transwell system in response to IL-8. The migrated
human neutrophils were brought into contact with various emm1
GAS strains (S1, Se235, and F482; non-STSS clinical isolates,
NIH60 and NIH186; and STSS isolates and their rgg mutants)
(TableS1),andthen the remaining viable neutrophilswerecounted.
Values shown are means 6 SD. *p,0.05, as estimated by Student’s
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Acknowledgments
We thank Dr. Y. Sato for her processing of histological samples and for Ms
Y. Nakamura for her excellent technical assistance.
Author Contributions
Conceived and designed the experiments: TI MA TM KK HW.
Performed the experiments: TI MA TM HH. Analyzed the data: TI
MA TM HH TS KK HW. Contributed reagents/materials/analysis tools:
TI MA TM HH. Wrote the paper: TI MA TM HH KK HW.
References
1. Bisno AL, Stevens DL (1996) Streptococcal infections of skin and soft tissues.
N Engl J Med 334: 240–245.
2. Ato M, Ikebe T, Kawabata H, Takemori T, Watanabe H (2008) Incompetence
of neutrophils to invasive group A streptococcus is attributed to induction of plural
Highly Frequent Mutations in STSS Isolates
PLoS Pathogens | www.plospathogens.org 16 April 2010 | Volume 6 | Issue 4 | e1000832virulence factors by dysfunction of a regulator. PLoS ONE 3: e3455.
doi:10.1371/journal.pone.0003455.
3. Walker M J, Hollands A, Sanderson-Smith ML, Cole JN, Kirk JK, et al. (2007)
DNase Sda1 provides selection pressure for a switch to invasive group A
streptococcal infection. Nat Med 13: 981–985.
4. Sumby P, Whitney AR, Graviss EA, DeLeo FR, Musser JM (2006) Genome-
wide analysis of group a streptococci reveals a mutation that modulates global
phenotype and disease specificity. PLoS Pathog 2: e5. doi:10.1371/journal.
ppat.0020005.
5. Miyoshi-Akiyama T, Ikebe T, Watanabe H, Uchiyama T, Kirikae T, et al.
(2006) Use of DNA arrays to identify a mutation in the negative regulator, csrR,
responsible for the high virulence of a naturally occurring type M3 group A
streptococcus clinical isolate. J Infect Dis 193: 1677–1684.
6. Beres SB, Sylva GL, Barbian KD, Lei B, Hoff JS, et al. (2002) Genome sequence
of a serotype M3 strain of group A Streptococcus: phage-encoded toxins, the
high-virulence phenotype, and clone emergence. Proc Natl Acad Sci USA 99:
10078–10083.
7. Nakagawa I, Kurokawa K, Yamashita A, Nakata M, Tomiyasu Y, et al. (2003)
Genome sequence of an M3 strain of Streptococcus pyogenes reveals a large-scale
genomic rearrangement in invasive strains and new insights into phage
evolution. Genome Res 13: 1042–1055.
8. Working Group on Severe Streptococcal Infections (1993) Defining the group A
streptococcal toxic shock syndrome. JAMA 269: 390–391.
9. Albert TJ, Dailidiene D, Dailide G, Norton JE, Kalia A, et al. (2005) Mutation
discovery in bacterial genomes: metronidazole resistance in Helicobacter pylori.N a t
Methods 2: 951–953.
10. Lyon WR, Gibson CM, Caparon MG (1998) A role for trigger factor and an rgg-
like regulator in the transcription, secretion and processing of the cysteine
proteinase of Streptococcus pyogenes. EMBO J 17: 6263–6275.
11. Chaussee MS, Ajdic D, Ferretti JJ (1999) The rgg gene of Streptococcus pyogenes
NZ131 positively influences extracellular SPE B production. Infect Immun 67:
1715–1722.
12. Chaussee MS, Watson RO, Smoot JC, Musser JM (2001) Identification of Rgg-
regulated exoproteins of Streptococcus pyogenes. Infect Immun 69: 822–831.
13. Chaussee MS, Sylva GL, Sturdevant DE, Smoot LM, Graham MR, et al. (2002)
Rgg influences the expression of multiple regulatory loci to coregulate virulence
factor expression in Streptococcus pyogenes. Infect Immun 70: 762–770.
14. Hollands A, Aziz RK, Kansal R, Kotb M, Nizet V, et al. (2008) A naturally
occurring mutation in ropB suppresses SpeB expression and reduces M1T1
group A streptococcal systemic virulence. PLoS ONE 3: e4102. doi:10.1371/
journal.pone.0004102.
15. Madden JC, Ruiz N, Caparon M (2001) Cytolysin-Mediated Translocation
(CMT): A Functional Equivalent of Type III Secretion in Gram-Positive
Bacteria. Cell 104: 143–152.
16. Dmitriev AV, McDowell EJ, Kappeler KV, Chaussee MA, Rieck LD, et al.
(2006) The Rgg regulator of Streptococcus pyogenes influences utilization of
nonglucose carbohydrates, prophage induction, and expression of the NAD-
glycohydrolase virulence operon. J Bacteriol 188: 7230–7241.
17. Dmitriev AV, McDowell EJ, Chaussee MS (2008) Inter- and intraserotypic
variation in the Streptococcus pyogenes Rgg regulon. FEMS Microbiol Lett 284:
43–51.
18. Graham MR, Smoot LM, Migliaccio CA, Virtaneva K, Sturdevant DE, et al.
(2002) Virulence control in group A Streptococcus by a two-component gene
regulatory system: global expression profiling and in vivo infection modeling.
Proc Natl Acad Sci 99: 13855–13860.
19. Trevin ˜o J, Perez N, Ramirez-Pen ˜a E, Liu Z, Shelburne SA, 3rd, et al. (2009)
CovS simultaneously activates and inhibits the CovR-mediated repression of
distinct subsets of group A Streptococcus virulence factor-encoding genes. Infect
Immun 77: 3141–3149.
20. Bricker AL, Carey VJ, Wessels MR (2005) Role of NADase in virulence in
experimental invasive group A streptococcal infection. Infect Immun 73:
6562–6566.
21. Sun H, Ringdahl U, Homeister JW, Fay WP, Engleberg NC, et al. (2004)
Plasminogen is a critical host pathogenicity factor for group A streptococcal
infection. Science 305: 1283–1286.
22. Kreikemeyer B, McIver KS, Podbielski A (2003) Virulence factor regulation and
regulatory networks in Streptococcus pyogenes and their impact on pathogen-host
interactions. Trends Microbiol 11: 224–232.
23. Kotb M, Norrby-Teglund A, McGeer A, El-Sherbini H, Dorak MT, et al. (2002)
An immunogenetic and molecular basis for differences in outcomes of invasive
group A streptococcal infections. Nat Med 8: 1398–1404.
24. Factor SH, Levine OS, Schwartz B, Harrison LH, Farley MM, et al. (2003)
Invasive group A streptococcal disease: risk factors for adults. Emerg Infect Dis
9: 970–977.
25. Gladysheva IP, Turner RB, Sazonova IY, Liu L, Reed GL (2003)
Coevolutionary patterns in plasminogen activation. Proc Natl Acad Sci USA
100: 9168–9172.
26. Miller LG, Perdreau-Remington F, Rieg G, Mehdi S, Perlroth J, et al. (2005)
Necrotizing fasciitis caused by community-associated methicillin-resistant
Staphylococcus aureus in Los Angeles. N Engl J Med 352: 1445–1453.
27. Chambers HF (2005) Community-associated MRSA-resistance and virulence
converge. N Engl J Med 352: 1485–1487.
28. Voyich JM, Braughton KR, Sturdevant DE, Whitney AR, Saı ¨d-Salim B, et al.
(2005) Insights into mechanisms used by Staphylococcus aureus to avoid destruction
by human neutrophils. J Immunol 175: 3907–3919.
29. Wang R, Braughton KR, Kretschmer D, Bach TH, Queck SY, et al. (2007)
Identification of novel cytolytic peptides as key virulence determinants for
community-associated MRSA. Nat Med 13: 1510–1514.
30. Ikebe T, Hirasawa K, Suzuki R, Ohya H, Isobe J, et al. (2007) Distribution of
emm genotypes among group A streptococus isolates from patients with severe
invasive streptococcal infections in Japan, 2001-2005. Epidemiol Infect 135:
1227–1229.
31. Tao L, LeBlanc DJ, Ferretti JJ (1992) Novel streptococcal integration shuttle
vectors for gene cloning and inactivation. Gene 120: 105–110.
32. Perez-Casal J, Price JA, Maguin E, Scott JR (1993) An M protein with a single C
repeat prevents phagocytosis of Streptococcus pyogenes: use of a temperature-
sensitive shuttle vector to deliver homologous sequences to the chromosome of S.
pyogenes. Mol Microbiol 8: 809–819.
33. Ikebe T, Hirasawa K, Suzuki R, Isobe J, Tanaka D, et al. (2005) Antimicrobial
susceptibility survey of Streptococcus pyogenes isolated from severe invasive group A
streptococcal infections in Japan. Antimicrob Agents Chemother 49: 788–790.
34. Ikebe T, Endo M, Ueda Y, Okada K, Suzuki R, et al. (2004) The genetic
properties of Streptococcus pyogenes emm49 genotype strains recently emerged
among severe invasive infections in Japan. Jpn J Infect Dis 57: 187–188.
35. Inagaki Y, Konda T, Murayama S, Yamai S, Matsushima A, et al. (1997)
Serotyping of Streptococcus pyogenes isolates from common and severe invasive
infections in Japan from 1990 to 1995. Epidemiol Infect 119: 41–48.
36. Morita M, Ikebe T, Watanabe H (2004) Consideration of the cysteine protease
activity for the serological M typing of clinical Streptococcus pyogenes isolates.
Miclobiol Immunol 48: 779–782.
37. Ikebe T, Wada A, Inagaki Y, Sugama K, Suzuki R, et al. (2002) Dissemination
of the phage-associated novel superantigen gene speL in recent invasive and
noninvasive Streptococcus pyogenes M3/T3 isolates in Japan. Infect Immun 70:
3227–3233.
38. Ikebe T, Endoh M, Watanabe H (2005) Increased expression of the ska gene in
emm49-genotyped Streptococcus pyogenes strains isolated from patients with severe
invasive streptococcal infections. Jpn J Infect Dis 58: 272–275.
39. Levin JC, Wessels MR (1998) Identification of csrR/csrS, a genetic locus that
regulates hyaluronic acid capsule synthesis in group A streptococcus. Mol Microbiol
30: 209–219.
40. Inagaki Y, Myouga F, Kawabata H, Yamai S, Watanabe H (2000) Genomic
differences in Streptococcus pyogenes serotype M3 between recent isolates associated
with toxic shock-like syndrome and past clinical isolates. J Infect Dis 181:
975–983.
41. Ikebe T, Wada A, Inagaki Y, Sugama K, Suzuki R, et al. (2002) Dissemination
of the phage-associated novel superantigen gene speL in recent invasive and
noninvasive Streptococcus pyogenes M3/T3 isolates in Japan. Infect Immun 70:
3227–3233.
Highly Frequent Mutations in STSS Isolates
PLoS Pathogens | www.plospathogens.org 17 April 2010 | Volume 6 | Issue 4 | e1000832